Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.42 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.41 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | PPIA | P62937 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2625917 | 1.00 | LMNA (0.43) | LMNASMN1; SMN2SCN8AAVPR2GPR27 | |
| SCHEMBL10310695 | 1.00 | LMNA (0.43) | LMNASMN1; SMN2SCN8AAVPR2GPR27 | |
| SCHEMBL10310676 | 1.00 | LMNA (0.43) | LMNASMN1; SMN2SCN8AAVPR2GPR27 | |
| SCHEMBL10310827 | 1.00 | LMNA (0.43) | LMNASMN1; SMN2SCN8AAVPR2GPR27 | |
| SCHEMBL10310713 | 1.00 | LMNA (0.43) | LMNASMN1; SMN2SCN8AAVPR2GPR27 | |
| SCHEMBL14280192 | 0.94 | LMNA (0.43) | LMNASMN1; SMN2SCN8AAVPR2GPR27 | |
| SCHEMBL2625916 | 0.91 | KDM4E (0.42) | SCN8AKMT2ASCN3AMEN1SCN9A | |
| SCHEMBL10310753 | 0.91 | SCN8A (0.42) | LMNASMN1; SMN2SCN8AAVPR2GPR27 | |
| SCHEMBL2626111 | 0.91 | SCN8A (0.42) | LMNASMN1; SMN2SCN8AAVPR2GPR27 | |
| SCHEMBL2626167 | 0.91 | SCN8A (0.42) | LMNASMN1; SMN2SCN8AAVPR2GPR27 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | LMNA 3348/4885SMN1; SMN2 600/4885SCN8A 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.